What Really Happens After You Stop GLP-1s: New Trial Data Explained (Updated for 2026)
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Updated: September 2026
Most people regain a large share of the weight after stopping, and the health improvements fade along with it. That has been clear for years. What changed in 2026 is that a trial finally tested a third option between staying on a full dose and stopping altogether, and a lower maintenance dose held onto most of the result.
Who This Helps
This is for you if you're thinking about stopping, have been told your coverage is ending, or want to know what to expect before you start. If you're early in treatment and wondering whether it's working at all, our article covering what to expect in the first six weeks is the better starting point.
A lower maintenance dose held most of the loss
This finding wasn't available when we first published this article. In a randomized trial published in May 2026, people who had lost weight on tirzepatide were moved either to a reduced 5 mg maintenance dose or to placebo. At week 112, the maintenance group was down 16.6% from where they started, against 9.9% for placebo (The Lancet).
That introduces a new solution to what to do when you reach maintenance. The choice people usually describe is continue or stop. The trial suggests a middle setting exists, and that it holds most of the benefit at a reduced cost. Whether it's affordable or available to you is a separate conversation with your prescriber, but it's now a real option backed by a trial rather than a hopeful idea.
How much comes back if you do stop
- Semaglutide, one year after withdrawal. Participants regained about two thirds of what they had lost. Having lost 17.3%, they were 5.6% below their starting weight at week 120 (Diabetes Obesity and Metabolism). Blood pressure, HbA1c and lipids also drifted back toward baseline.
- Tirzepatide, switched to placebo. Weight rose 14.0% over the following year, while those who continued lost a further 5.5% (JAMA). Of those who continued, 89.5% kept at least 80% of their loss, against 16.6% of those switched off.
- Semaglutide, continued versus withdrawn. In a trial designed around that comparison, the group switched to placebo gained 6.9% while the continuing group lost a further 7.9% (JAMA).
A 2026 analysis broke the tirzepatide result down by how much people regained, and found that the cardiometabolic benefits tracked the regain rather than disappearing on a schedule (JAMA Internal Medicine). People who regained less than a quarter of what they lost held on to waist, non-HDL cholesterol and fasting insulin gains, though blood pressure and HbA1c still drifted back even in that group. Roughly four in five regained more than a quarter.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Most people stop within two years
The trial numbers describe what happens when people stop. Real-world data describes how often they do. In a cohort of 125,474 adults, 53.6% had stopped within a year and 72.2% within two (JAMA Network Open). Discontinuation was higher in people without type 2 diabetes, at 64.8%, than in people with it, at 46.5%.
Cost is a major driver, and 2026 has made that worse as employers drop coverage. Published estimates of how often cost is the reason vary a lot depending on who is being counted, so no single figure describes everybody.
Three things nobody can tell you yet
These unknowns matter, because confident advice gets given about all three.
- Whether tapering beats stopping abruptly. No randomized trial has compared them. A trial designed to answer it began recruiting in March 2026 and isn't expected to report until around 2030 (PLOS One). Clinicians who prefer a taper are using judgment rather than evidence, which is useful to know when you're told one way is safer.
- What the regained weight is made of. Body composition was measured during the losing phase in the major trials, not during regain. So whether people come back with proportionally more fat than they left with is an open question, and anyone stating it confidently is going past the data.
- Who keeps it off. There's no well-powered study identifying who maintains weight after stopping. Averages are all that exist, and an average isn't a prediction about you.
What to actually do with this
If stopping is a choice, the maintenance-dose finding is worth raising with your prescriber before you assume the options are all or nothing. If stopping isn't a choice, because coverage ended or side effects made it untenable, the trial data argues for planning the landing rather than treating it as a failure. The improvements that fade are the ones tied to the weight, so what you hold onto is what matters.
Expect appetite to return, and expect it to feel like a change in you rather than a change in your medication. That's the part people find hardest, and knowing it's coming helps. Our piece on long-term side effects covers the other half of the picture, which is what staying on looks like.
Final Takeaway
The headline finding has not changed: stop, and most of the weight comes back, along with the blood pressure and blood sugar improvements that came with losing it. What has changed is that continuing at full dose is no longer the only way to hold the result, because a reduced maintenance dose now has trial evidence behind it. If you're facing this decision, that's the question to ask first. And if you do stop, do it with a plan and a follow-up date rather than by running out of prescription. The people who do best are the ones who treated the landing as seriously as the takeoff.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Do you have to take GLP-1s forever?
Not necessarily, and a 2026 trial found that dropping to a lower maintenance dose held most of the weight loss rather than requiring a full dose indefinitely. Stopping altogether does tend to be followed by substantial regain, so the realistic framing is ongoing treatment at some level rather than a course you finish.
How fast does weight come back after stopping?
In the trials, over roughly a year. One semaglutide follow-up found about two thirds of the lost weight returned within twelve months of stopping. Real-world regain tends to be slower than trial regain, though it still happens.
Is it better to taper the dose than stop suddenly?
Nobody knows yet. No randomized trial has compared tapering with stopping, and the trial designed to answer it only began recruiting in 2026. Clinicians who recommend a taper are drawing on experience rather than published evidence.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
Learn smart strategies to schedule your weekly GLP-1 injection when travelling or during big events—stay on track without disruptions.
Employers are dropping GLP-1 coverage. See how to check any plan's drug list before open enrollment closes, and what the conditions mean.
Tirzepatide can make the birth control pill less reliable for 4 weeks after each dose change. Semaglutide doesn't. See what your label says.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.